This Week in Surgery — Jun 25, 2026

Welcome to This Week in Surgery. This week we're covering ten notable papers spanning major advancements in reconstructive and transplant surgery, refined techniques in general and oncological abdominal operations, and long-term comparative data that challenge established surgical paradigms. Let's dive in.

We begin this week with a series of remarkable papers that push the boundaries of reconstructive and transplant surgery, showcasing how novel technologies and bioengineering are redefining organ rescue and replacement. In a landmark study published in The Lancet, researchers report the first-in-human combined bladder and kidney transplantation, demonstrating the technical feasibility of vascularized composite bladder allografting [10]. Current surgical treatments for terminal bladder dysfunction rely on intestinal-based reconstructive approaches, which carry substantial long-term morbidity, particularly in immunosuppressed patients. To address this, the investigators initiated a trial of deceased-donor bladder or combined bladder-kidney transplantation. The first-in-human case was performed on a 41-year-old male with end-stage kidney disease and a non-functional, terminal bladder who had been on peritoneal dialysis for seven years. Utilizing organs from an ABO-compatible deceased donor, the surgical team completed the eight-hour operation with excellent graft perfusion and no immediate intraoperative complications. Although the patient experienced a Clavien-Dindo grade four complication on postoperative day 25—specifically, a urine leak from the suprapubic tube tract and surgical wound breakdown that required operative management—he made a good recovery. At more than six months post-transplantation, the patient demonstrated preserved renal function with an estimated glomerular filtration rate of 52 to 55 milliliters per minute, alongside intact bladder sensation, an appropriate urge to void, a bladder capacity of 600 milliliters, complete continence, and spontaneous voiding. Serial biopsies confirmed no cellular or antibody-mediated rejection under standard triple-therapy immunosuppression. This proof-of-concept trial suggests that bladder transplantation is a viable option for select patients with terminal bladder dysfunction, particularly those who already require or are undergoing concurrent immunosuppression.

Expanding on the theme of organ optimization and evaluation, a study in Science Translational Medicine introduces a noninvasive optical technique designed to address the critical shortage of viable donor organs [3]. Investigators evaluated polarization-sensitive optical coherence tomography, or PS-OCT, as a multiparameter tool to assess donor liver viability across the entire organ surface. Currently, assessing marginal livers from extended-criteria donors relies on highly invasive, localized needle biopsies. By applying PS-OCT imaging to multiple regions of human donor livers and using machine learning and texture analysis, the researchers achieved a correlation of greater than 80 percent with traditional histopathological findings for key features such as hepatic steatosis, fibrosis, inflammation, and necrosis. Crucially, the PS-OCT measurements strongly correlated with the functional performance of the livers during normothermic machine perfusion and with subsequent clinical post-transplant outcomes. This technology offers a rapid, noninvasive, and comprehensive surface-mapping approach that could safely reduce the discard rate of high-risk donor livers and expand the transplant pool. Meanwhile, in the field of prenatal reconstruction, The Lancet published a phase one study evaluating a novel, noninvasive method to reverse fetoscopic endoluminal tracheal occlusion, or FETO, in fetuses with severe congenital diaphragmatic hernia [9]. Traditionally, FETO requires a second invasive in-utero procedure to remove or puncture the tracheal balloon before delivery. This clinical trial evaluated the Smart-TO device, a tracheal occlusion balloon designed to spontaneously deflate when exposed to the magnetic field of a standard magnetic resonance imaging machine. Across clinical sites in Belgium and France, 47 pregnant patients underwent FETO, and the device was successfully placed in 46 fetuses. At approximately 34 weeks of gestation, magnetic resonance imaging-induced deflation was attempted, achieving a 100 percent success rate. At delivery, the empty balloon was confirmed to be outside the fetal airways in all cases. While there were 14 neonatal deaths attributed to severe pulmonary hypoplasia and two cases of transient tracheomalacia among survivors, no serious adverse events were related to the device itself. This represents a substantial clinical advance by successfully eliminating the need for a second high-risk intrauterine intervention to restore airway patency.

Moving into abdominal and oncological surgery, several new studies provide critical clarity on timing, surgical margins, and anatomical preservation. First, a large population-based cohort study in JAMA Surgery addresses the ongoing clinical debate regarding the management of mild gallstone-related acute pancreatitis [4]. While clinical guidelines strongly recommend same-admission cholecystectomy, the procedure is frequently deferred, and clinicians often opt for endoscopic retrograde cholangiopancreatography, or ERCP, as an interim or sole strategy. Analyzing national registry data from Sweden on over 9,500 adults with a brief hospital stay of 10 days or less, researchers compared index-admission cholecystectomy, ERCP only, and no intervention. The results were stark: recurrence of acute pancreatitis occurred in only 3.4 percent of the cholecystectomy group, compared to 4.9 percent in the ERCP-only group, and a high 17.5 percent among those who received no intervention. In adjusted models, having no intervention was associated with an approximate six-fold increase in the risk of recurrent pancreatitis compared to same-admission cholecystectomy. For patients treated with ERCP only, the risk of recurrence was highly concentrated, peaking between 8 and 14 days post-discharge, after which the long-term recurrence rate stabilized to levels comparable to surgery. However, other gallstone-related complications—such as acute cholecystitis and choledocholithiasis—remained exceedingly common in the ERCP-only and no-intervention groups, occurring in roughly 20 percent and 16 percent of patients, respectively, compared to just 1.6 percent in the same-admission cholecystectomy group. These findings provide robust support for prioritizing same-admission cholecystectomy in all eligible patients to prevent early, preventable readmissions and secondary biliary complications.

In colorectal surgery, another multicenter randomized clinical trial in JAMA Surgery investigated whether the level of inferior mesenteric artery ligation during minimally invasive low anterior resection for rectal cancer impacts anastomotic integrity [5]. Proponents of low ligation—preserving the left colic artery—argue it improves anastomotic perfusion and reduces leaks, while proponents of high ligation argue it facilitates apical lymph node dissection and mobilization. The trial randomized 293 patients to either high or low ligation. Symptomatic anastomotic leakage occurred in 4.9 percent of the low-ligation group and 6.0 percent of the high-ligation group, a difference that was not statistically significant. Postoperative 30-day morbidity was also statistically similar between the groups, standing at 14 percent for low ligation and 22 percent for high ligation. Furthermore, at 12 months postoperatively, there were no significant differences in bowel function, as measured by Low Anterior Resection Syndrome scores, or in urinary and sexual function. These findings suggest that both high and low ligation of the inferior mesenteric artery are safe, feasible, and yield comparable short-term safety and long-term functional outcomes, allowing surgeons to choose the technique based on anatomical and oncological preferences without fearing a significant impact on anastomotic leak rates. In the realm of hepato-pancreato-biliary surgical oncology, a retrospective study in the Annals of Surgery redefined how we evaluate radial margin distance in patients undergoing resection for perihilar cholangiocarcinoma [7]. Traditionally, a positive margin is defined simply by the presence of cancer cells at the cut edge. However, this study of 658 patients established that a binary definition is insufficient. By examining the precise microscopic distance of the radial margin, researchers identified two critical cutoffs: 0 millimeters and 1.0 millimeter. Patients with a margin of exactly 0 millimeters had the highest hazard for overall mortality. The hazard decreased as the margin distance increased, plateauing at 1.0 millimeter. When patients were categorized into three groups—0 millimeters, more than 0 but less than 1.0 millimeter, and 1.0 millimeter or greater—the 5-year cumulative recurrence rates were 83.5 percent, 68.8 percent, and 23.9 percent, respectively. Local recurrence rates followed a similar pattern, and the 5-year overall survival rate was 78.5 percent in the 1.0 millimeter or greater group compared to only 21.8 percent in the 0 millimeter group. This simple, dual-cutoff classification of 0 and 1.0 millimeter provides a highly accurate tool for post-surgical risk stratification, helping clinicians identify patients who may benefit most from aggressive adjuvant therapies.

Our third theme highlights the invaluable role of long-term, ten-year follow-up data in evaluating the durability and safety of surgical and cellular interventions. Writing in JAMA Surgery, the United States Pelvic Floor Disorders Network presented the ten-year outcomes of a randomized clinical trial comparing vaginal sacrospinous hysteropexy with mesh to vaginal hysterectomy with uterosacral ligament suspension for symptomatic uterovaginal prolapse [6]. Prolapse trials rarely track patients for a decade, making these findings critical for counseling postmenopausal women. Among the 175 patients analyzed, the primary composite failure rate—defined as retreatment, prolapse extending beyond the hymen, or bothersome symptoms—was lower in the uterine-preserving mesh hysteropexy group at 40 percent, compared to 53 percent in the hysterectomy group. This represented a 36 percent reduction in the risk of treatment failure for the hysteropexy group. Importantly, both groups maintained excellent, durable improvements in patient-reported pelvic symptoms, sexual function, and quality of life, with no significant differences in long-term complications or dyspareunia. While the expected progressive separation in durability between the mesh and native tissue procedures in the later years did not materialize, vaginal mesh hysteropexy remains a highly effective, low-risk, uterine-sparing alternative for patients seeking reconstructive surgery. In another impressive ten-year follow-up, The New England Journal of Medicine published long-term results of anti-CD19 chimeric antigen receptor, or CAR, T-cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas [2]. While this cellular therapy has revolutionized hematologic oncology, its decade-long curative potential has remained uncertain. In this cohort of 38 heavily pretreated patients, the ten-year lymphoma-free survival was 32 percent for those with large B-cell lymphoma and 47 percent for those with follicular lymphoma. No relapses occurred beyond five and a half years, suggesting that patients who reach this milestone may indeed be cured. However, long-term monitoring is essential: a second primary cancer developed in 9 patients, resulting in a ten-year cumulative incidence of 21 percent, and the ten-year non-relapse-related mortality was 18 percent. Persistent B-cell aplasia was noted in 44 percent of long-term responders, but late hematologic toxicities were rare. These findings confirm that a single infusion of CAR T-cell therapy can induce decade-long, drug-free remissions in a significant subset of patients, though clinicians must remain vigilant regarding late secondary malignancies.

Our final theme addresses the intersection of surgical technology and translational science, questioning whether rapid technological adoption translates to improved patient safety and exploring novel molecular pathways. A large-scale retrospective cohort study in the Journal of the American College of Surgeons utilized the national metabolic and bariatric surgery accreditation database to compare robotic-assisted bariatric surgery with conventional laparoscopy [8]. Analyzing nearly 950,000 adult patients undergoing sleeve gastrectomy, gastric bypass, or duodenal switch procedures across United States centers, researchers evaluated 30-day serious adverse events. After adjusting for patient demographics, comorbidities, and conversion status, the study found that robotic assistance was not associated with improved short-term safety. In fact, robotic surgery was associated with a small but statistically significant excess risk of serious adverse events across all procedure types, ranging from an additional 2.4 events per 1,000 cases for primary sleeve gastrectomies to 15.2 excess events per 1,000 cases for complex duodenal switch procedures. This excess risk was primarily driven by higher rates of readmission, reoperation, and reintervention, while mortality remained low and identical between platforms. Although this excess risk appeared to attenuate slightly over the study years, these national registry findings suggest that the widespread, rapid adoption of robotic platforms in standardized, low-morbidity bariatric procedures does not offer immediate short-term safety advantages and highlights the need for cautious technology implementation. Transitioning to the basic science frontier, a study in Nature uncovers a novel molecular pathway regulating cholesterol metabolism that could pave the way for future therapeutic interventions [1]. The researchers identified a pathway regulated by Ral GTPases that directly links dietary cholesterol to the degradation of the hepatic low-density lipoprotein receptor, or LDLR. Chronic dietary cholesterol intake activates Ral proteins, which then recruit the endocytic RalBP1-REPS1 complex to internalize LDLR and route it to lysosomes for degradation by the protease cathepsin A, rather than allowing the receptor to recycle to the cell surface. This process occurs independently of traditional transcriptional regulation or PCSK9. Crucially, the study showed that pharmacological inhibition of cathepsin A activity successfully prevents LDLR degradation, thereby restoring hepatic LDLR function and improving systemic cholesterol clearance. This newly defined pathway offers a promising therapeutic target for patients with hypercholesterolemia and cardiovascular disease who are resistant to current lipid-lowering therapies.

If you only have time for one paper this week, make it the population-based study in JAMA Surgery on the timing of cholecystectomy after gallstone-related acute pancreatitis [4]. This paper provides definitive, high-quality evidence that same-admission cholecystectomy is vastly superior to both ERCP-only and delayed strategies in preventing early readmissions for recurrent pancreatitis and secondary biliary complications, offering a clear mandate to align clinical practice with guideline recommendations.

Here are the key takeaways from this week in Surgery. First, prioritize same-admission cholecystectomy for patients with mild gallstone pancreatitis, as delaying surgery or relying solely on ERCP leads to high rates of recurrent pancreatitis and other biliary complications within the first two weeks of discharge. Second, in minimally invasive low anterior resection for rectal cancer, both high and low ligation of the inferior mesenteric artery are safe and comparable, with no significant differences in anastomotic leak rates or long-term bowel, urinary, and sexual function. Third, when resecting perihilar cholangiocarcinoma, utilize a dual-cutoff radial margin classification of 0 and 1.0 millimeter to accurately stratify postoperative recurrence and overall survival. Fourth, vaginal sacrospinous hysteropexy with mesh is a highly durable, low-risk, uterine-sparing option that achieves lower ten-year composite failure rates compared to vaginal hysterectomy with native tissue suspension. Finally, national registry data reveal that robotic-assisted bariatric surgery does not improve short-term safety over conventional laparoscopy and is associated with a small excess risk of 30-day serious adverse events, emphasizing the need for cautious technology implementation and further prospective evaluation.

That's your roundup for This Week in Surgery. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.